Holen Sie sich die Stockscreener-App
15.11
1.27%
0.19
Handel nachbörslich:
15.11
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TVTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$14.92
Offen:
$14.73
24-Stunden-Volumen:
1.15M
Relative Volume:
0.68
Marktkapitalisierung:
$1.32B
Einnahmen:
$203.45M
Nettoeinkommen (Verlust:
$-351.45M
KGV:
-3.3209
EPS:
-4.55
Netto-Cashflow:
$-369.41M
1W Leistung:
+1.89%
1M Leistung:
-26.40%
6M Leistung:
-16.52%
1J Leistung:
+164.16%
1-Tages-Spanne:
$14.71
$15.87
1-Wochen-Bereich:
$14.13
$15.87
52-Wochen-Spanne:
$5.12
$25.29
Travere Therapeutics Inc Stock (TVTX) Company Profile
Firmenname
Travere Therapeutics Inc
Sektor
Branche
Telefon
888-969-7879
Adresse
3611 VALLEY CENTRE DR, SAN DIEGO
Vergleichen Sie TVTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
15.11 | 1.32B | 203.45M | -351.45M | -369.41M | -4.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-10-21 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-09-09 | Hochstufung | Guggenheim | Neutral → Buy |
| 2024-03-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-12-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-11-20 | Eingeleitet | Citigroup | Neutral |
| 2023-09-22 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-09-21 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-09-06 | Fortgesetzt | Evercore ISI | Outperform |
| 2023-07-21 | Eingeleitet | JP Morgan | Overweight |
| 2023-06-07 | Fortgesetzt | Piper Sandler | Neutral |
| 2023-05-22 | Eingeleitet | TD Cowen | Outperform |
| 2023-05-05 | Hochstufung | Bryan Garnier | Sell → Neutral |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2023-02-21 | Hochstufung | Wedbush | Neutral → Outperform |
| 2022-12-14 | Eingeleitet | Stifel | Hold |
| 2022-12-05 | Eingeleitet | Wells Fargo | Overweight |
| 2022-09-21 | Eingeleitet | Bryan Garnier | Sell |
| 2022-07-14 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-03-31 | Eingeleitet | Piper Sandler | Overweight |
| 2022-02-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-26 | Herabstufung | Wedbush | Outperform → Neutral |
Alle ansehen
Travere Therapeutics Inc Aktie (TVTX) Neueste Nachrichten
Travere Therapeutics, Inc. (NASDAQ:TVTX) Shares Purchased by Invesco Ltd. - Defense World
How to Take Advantage of moves in (TVTX) - news.stocktradersdaily.com
Q1 Earnings Estimate for TVTX Issued By Wedbush - Defense World
Geode Capital Management LLC Raises Position in Travere Therapeutics, Inc. (NASDAQ:TVTX) - Defense World
Franklin Resources Inc. Acquires New Position in Travere Therapeutics, Inc. (NASDAQ:TVTX) - Defense World
Wellington Management Group LLP Makes New $583,000 Investment in Travere Therapeutics, Inc. (NASDAQ:TVTX) - Defense World
Travere Therapeutics (NASDAQ:TVTX) Given “Buy” Rating at Guggenheim - Defense World
Travere therapeutics CFO Cline sells $630 in shares By Investing.com - Investing.com India
Travere therapeutics CFO Cline sells $630 in shares - Investing.com
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 11, 2025 - BioSpace
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | TVTX Stock News - GuruFocus
Travere Therapeutics price target lowered to $30 from $32 at Scotiabank - Yahoo Finance
Scotiabank Updates Price Target for Travere Therapeutics (TVTX) Amid Drug Data Release | TVTX Stock News - GuruFocus
Revenues Working Against Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Share Price Following 26% Dive - simplywall.st
Scotiabank Remains a Buy on Travere Therapeutics (TVTX) - The Globe and Mail
Canaccord Increases Price Target for Travere Therapeutics (TVTX) to $47 | TVTX Stock News - GuruFocus
Canaccord raises Travere stock target to $47, maintains Buy rating By Investing.com - Investing.com Canada
Canaccord raises Travere stock target to $47, maintains Buy rating - Investing.com
Retrophin, Inc. entered into an agreement to acquire Desert Gateway, Inc. from Rosetta Granite, Inc. and other shareholders in a reverse merger transaction. - MarketScreener
Travere Therapeutics (TVTX) Receives a Buy from Wells Fargo - The Globe and Mail
Focal Segmental Glomerulosclerosis Pipeline Analysis - openPR.com
Novartis Has A Slight Edge On Travere — Why Analysts Aren't Worried - MSN
Cantor Fitzgerald stays bullish on Travere Therapeutics stock By Investing.com - Investing.com UK
Trading (TVTX) With Integrated Risk Controls - news.stocktradersdaily.com
Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $31.00 at Bank of America - Defense World
The Analyst Verdict: Travere Therapeutics In The Eyes Of 7 Experts - Benzinga
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the National Kidney Foundation Spring Clinical Meetings 2025 - BioSpace
Is Travere Therapeutics, Inc. (NASDAQ:TVTX) the Best Small Cap Stock to Buy Before They Explode? - Insider Monkey
10 Best Small-Cap Stocks to Buy Before They Explode - Insider Monkey
Nephrologists Embrace Earlier, More Aggressive IgAN Treatment as Branded Therapies from Calliditas, Travere, and Novartis Continue to Gain Traction, According to Spherix Global Insights - Yahoo Finance
When (TVTX) Moves Investors should Listen - news.stocktradersdaily.com
Travere seeks FDA approval for potential FSGS treatment By Investing.com - Investing.com Australia
Travere rises on co's marketing application for kidney disease drug - TradingView
Travere seeks FDA approval for potential FSGS treatment - Investing.com India
Travere Therapeutics Submits sNDA To FDA For Approval Of Filspari (Sparsentan) For The Treatment Of FSGS - Marketscreener.com
Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS - The Manila Times
Travere Therapeutics Submits sNDA for FILSPARI as Potential First FDA-Approved Treatment for FSGS - Nasdaq
Breakthrough: First-Ever FSGS Treatment Could Get FDA Green LightFILSPARI Shows Superior Results - StockTitan
High Growth Tech Stocks In The US With Promising Potential - Simply Wall St
US Bancorp DE Has $554,000 Stock Position in Travere Therapeutics, Inc. (NASDAQ:TVTX) - Defense World
Travere Therapeutics Expands Team with 77,200 Shares in Strategic Equity Grants - Stock Titan
Travere Therapeutics at Leerink Conference: Filspari’s Promising Path - Investing.com
Focal Segmental Glomerulosclerosis Treatment Market Size - openPR
Is Eli Lilly Stock a Buy? - The Globe and Mail
Why Travere Therapeutics Inc. (TVTX) Went Up On Tuesday? - MSN
What To Expect From Travere Therapeutics Inc (TVTX) Q4 2024 Earnings - GuruFocus.com
Travere Therapeutics: Tricky Outlook Gives Me Pause For ThoughtDowngrade - Seeking Alpha
Finanzdaten der Travere Therapeutics Inc-Aktie (TVTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.15%
4.32%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):